Venofer^® (iron sucrose injection, USP) is a first-line IV iron choice in the treatment of iron deficiency anemia in:

• Non-Dialysis Dependent - Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving an erythropoietin
• Hemodialysis Dependent - Chronic Kidney Disease (HDD-CKD) patients receiving an erythropoietin
• Peritoneal Dialysis Dependent - Chronic Kidney Disease (PDD-CKD) patients receiving an erythropoietin

Only Venofer^® supports treatment safety and versatility with all of these features:

Over 50 years of worldwide clinical experience Dextran free Preservative free Available in convenient single-dose vials Nondialyzable No bolded or black box warnings		No test dose required Safety and efficacy confirmed in US clinical trials in non-dialysis and dialysis dependent - CKD patients HCPCS Code: J1756 (1 mg= 1service unit) for hemodialysis services provided on or after January 1, 2003
Recommended Dosage: NDD-CKD patients - Administration of a total cumulative dose of 1,000 mg 200 mg slow IV injection over 2 to 5 minutes on 5 different occasions within a 14 day period* HDD-CKD patients - Administration of a total cumulative dose of 1,000 mg over 10 consecutive dialysis sessions 100 mg slow IV injection over 2 to 5 minutes, or 100 mg in 100 mL 0.9% NaCl as an IV infusion over at least 15 minutes PDD-CKD patients - Administration of a total cumulative dose of 1,000 mg in 3 divided doses within a 28 day period  2 infusions of 300 mg over 1.5 hours 14 days apart followed by one 400 mg infusion over 2.5 hours 14 days later.  The Venofer ® dose should be diluted in a maximum of 250 mL 0.9% NaCl *There is limited experience with administration of an infusion of 500 mg of Venofer® in 250 mL 0.9% NaCl over 3.5 - 4 hours; hypotension occurred in 2 of 30 patients treated.

To learn more about Venofer^® and Anemia Management, click on a link in the column on the left side of this page. To see a presentation about the speed, safety, and versatility of Venofer^®, click here.




 

To view the complete Venofer^® Formulary Monograph, click here.

 

 


To report adverse drug events (ADEs) to Venofer® (iron sucrose injection, USP)
please call toll-free 1-800-734-9236


IMPORTANT SAFETY INFORMATION
Venofer ^® (iron sucrose injection, USP) is contraindicated in patients with evidence of iron overload, in patients with known hypersensitivity to Venofer ^® or any of its inactive components, and in patients with anemia not caused by iron deficiency.  Hypersensitivity reactions have been reported with IV iron products.  Hypotension has been reported frequently in hemodialysis dependent-CKD patients receiving IV iron, and has also been reported in non-dialysis dependent and peritoneal dialysis dependent-CKD patients receiving IV iron.  Hypotension following administration of Venofer^® may be related to rate of administration and total dose delivered.

In multi-dose efficacy studies in hemodialysis dependent-CKD patients (N=231), the most frequent adverse events (>5%), whether or not related to Venofer^® administration, were hypotension, cramps/leg cramps, nausea, headache, graft complications, vomiting, dizziness, hypertension, chest pain and diarrhea.  In post-marketing safety studies in hemodialysis dependent-CKD patients (N=1051), the most frequent adverse events reported (>1%) were congestive heart failure, sepsis and taste perversion.  In multi-dose efficacy studies in non-dialysis dependent-CKD patients (N=91), the most frequent adverse events ( ≥5%) whether or not related to Venofer^® administration, were taste disturbance, peripheral edema, diarrhea, constipation, nausea, dizziness, and hypertension.  In the study of peritoneal dialysis dependent-CKD patients (N= 75), the most frequent adverse events, whether or not related to Venofer^®, reported by ≥5% of these patients were diarrhea, peritoneal infection, vomiting, hypertension, pharyngitis, peripheral edema and nausea.
Please see Full Prescribing Information.

Venofer^® is manufactured under license from Vifor (International) Inc., Switzerland